I've decided not to reply or acknowledge posters l
Post# of 154183
(Total Views: 397)
Posted On: 07/31/2019 9:39:14 AM
I've decided not to reply or acknowledge posters like that anymore. They just want to rile up investors with incessant negativity, because they know some of us get pretty passionate about our investment.(guilty as charged here as well) They certainly are allowed, but emotions are what makes investing dangerous. We either turn a blind eye to signs a company is failing or we never see the turn around coming because we only looked for the negative spin on everything out of the CEOs mouth.
Right now I see cydy as burning cash, and needing funds. However I know as a last resort they have more shares to issue.
On the flip side they have a very promising drug for multiple indications on diseases that aren't rare(yet). So revenue and profitability are possible, and having heard the independent doctors share actual customers excitement over using leronlimab vs daily pills adds validity to NPs message that some of us have grown immune to.
I would also keep an eye on any potential litigation from RP because that is still an unknown that could hamper progress if legal battles for IP ensues.(we just dont know)
Until then I'll stay long because the potential is great due to efficacy, patient need, ease of use, and possibility of partnership agreements.
But also watch for possible litigation, mgmt execution of strategy, funding strategy pre revenue and profitability post revenue.
Happy investing!
Right now I see cydy as burning cash, and needing funds. However I know as a last resort they have more shares to issue.
On the flip side they have a very promising drug for multiple indications on diseases that aren't rare(yet). So revenue and profitability are possible, and having heard the independent doctors share actual customers excitement over using leronlimab vs daily pills adds validity to NPs message that some of us have grown immune to.
I would also keep an eye on any potential litigation from RP because that is still an unknown that could hamper progress if legal battles for IP ensues.(we just dont know)
Until then I'll stay long because the potential is great due to efficacy, patient need, ease of use, and possibility of partnership agreements.
But also watch for possible litigation, mgmt execution of strategy, funding strategy pre revenue and profitability post revenue.
Happy investing!
(2)
(0)